{
    "eid": "2-s2.0-85086325881",
    "title": "Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials",
    "cover-date": "2020-09-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Nephrology",
            "@code": "2727",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Urology",
            "@code": "2748",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Antidiabetic agents",
        "Cardiovascular outcomes",
        "DPP-4 inhibitors",
        "GLP-1 agonists",
        "Renal outcomes",
        "SGLT-2 inhibitors"
    ],
    "authors": [
        "Api Chewcharat",
        "Kullaya Takkavatakarn",
        "Suramath Isaranuwatchai",
        "Pisut Katavetin",
        "Kearkiat Praditpornsilpa",
        "Somchai Eiam-ong",
        "Paweena Susantitaphong"
    ],
    "citedby-count": 3,
    "ref-count": 41,
    "ref-list": [
        "Global prevalence of Type 2 diabetes over the next ten years (2018\u20132028)",
        "Microvascular and macrovascular complications of diabetes",
        "Diabetes and CKD in the United States Population, 2009\u20132014",
        "Molecular mechanisms of diabetic kidney disease",
        "Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study",
        "SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials",
        "Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials",
        "Renal outcomes of antidiabetic treatment options for Type 2 diabetes\u2014a proposed MARE definition",
        "Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control",
        "Empagliflozin and clinical outcomes in patients with Type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease",
        "Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment",
        "Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial",
        "Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy",
        "Dapagliflozin and cardiovascular outcomes in Type 2 diabetes",
        "Lixisenatide in patients with Type 2 diabetes and acute coronary syndrome",
        "Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes",
        "Liraglutide and renal outcomes in Type 2 diabetes",
        "Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind",
        "Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes",
        "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial",
        "Effect of sitagliptin on cardiovascular outcomes in Type 2 diabetes",
        "Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in Type 2 diabetes",
        "Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial",
        "Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial",
        "Effect of linagliptin vs placebo on major cardiovascular events in adults with Type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial",
        "Empagliflozin and progression of kidney disease in Type 2 diabetes",
        "Canagliflozin and cardiovascular and renal events in Type 2 diabetes",
        "Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial",
        "Renal outcomes in the exenatide study of cardiovascular event lowering (EXSCEL)",
        "Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin",
        "Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes",
        "Standards of medical care in diabetes\u20142019 Abridged for Primary Care Providers (2019)",
        "2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines",
        "2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)",
        "Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020",
        "Renoprotective effects of sodium-glucose cotransporter-2 inhibitors",
        "SGLT2 inhibition for the prevention and treatment of diabetic kidney disease: a review",
        "GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes",
        "Renal effects of DPP-4 inhibitors: a focus on microalbuminuria",
        "Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors",
        "GLP-1 receptor agonists and kidney protection"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60032499",
            "affilname": "Harvard T.H. Chan School of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032499",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022464",
            "affilname": "Chulabhorn Royal Academy",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022464",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}